ASCEND: A Study of Cardiovascular Events iN Diabetes
Diabetes Mellitus
About this trial
This is an interventional prevention trial for Diabetes Mellitus focused on measuring Diabetes Mellitus, Cardiovascular Disease, Aspirin, Omega-3 fatty acids, Primary prevention, Randomized Controlled Trial, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, n-3 fatty acid
Eligibility Criteria
Inclusion Criteria: Males or females with type 1 or type 2 diabetes mellitus. Aged ≥ 40 years. No previous history of vascular disease. No clear contra-indication to aspirin. No other predominant life-threatening medical problem. Exclusion Criteria: Definite history of myocardial infarction, stroke or arterial revascularisation procedure. Currently prescribed aspirin, warfarin or any other blood thinning medication.
Sites / Locations
- Clinical Trial Service Unit, NDPH, University of Oxford
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Aspirin + Omega-3 Ethyl Esters
Aspirin + Placebo Omega-3 Ethyl Esters
Placebo Aspirin + Omega-3 Ethyl Esters
Placebo Aspirin + Placebo Omega-3 Ethyl Esters
Participants receive 100mg of aspirin once daily and 1g of omega-3 ethyl esters once daily.
Participants receive 100mg of aspirin once daily and placebo omega-3 ethyl esters once daily.
Participants receive placebo aspirin once daily and 1g of omega-3 ethyl esters once daily.
Participants receive placebo aspirin once daily and placebo omega-3 ethyl esters once daily.